New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
12:00 EDTOMEDOncoMed falls 13.4%
OncoMed is down 13.4%, or $3.33, to $21.57
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
07:26 EDTOMEDCredit Suisse to hold a conference
Antibody Day 2015 to be held in New York on May 6.
April 30, 2015
13:58 EDTOMEDOncoMed cancer pipeline being undervalued, says Piper Jaffray
Subscribe for More Information
April 28, 2015
10:51 EDTOMEDOncoMed management to meet with JMP Securities
Subscribe for More Information
April 23, 2015
10:01 EDTOMEDOncoMed to host research and development day
Subscribe for More Information
April 22, 2015
08:35 EDTOMEDOncoMed initiates dosing in randomized Phase 2 clinical trial of demcizumab
OncoMed Pharmaceuticals announced that dosing has begun in the randomized Phase 2 clinical trial of demcizumab in patients with first-line metastatic pancreatic cancer. The double-blind, placebo-controlled Phase 2 "YOSEMITE" clinical trial is designed to compare the efficacy and safety of demcizumab combined with standard of care Abraxane plus gemcitabine in patients with first-line metastatic pancreatic cancer. The primary endpoint of the trial is progression-free survival. Secondary endpoints include overall survival, response rate, duration of response, safety, immunogenicity and pharmacokinetics. Approximately 200 patients will be randomized into one of three study arms. Patients in Arm 1 will receive Abraxane plus gemcitabine plus placebo. Patients in Arm 2 will receive standard of care plus one course of demcizumab 3.5 mg/kg every two weeks for 70 days. Patients in Arm 3 will receive standard of care plus a second course of demcizumab following a 100-day wash out period. The Phase 2 trial is being conducted at approximately 50 centers in the U.S., Canada, Europe and Australia.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use